

EXECUTIVE SUMMARY

First quarter 2025




Main figures €Mn


Op. Revenue	EBITDA	EBIT
154.9 (+2%)	30.3 (+17%)	23.0 (+19%)
Net profit	Capex	Net debt
18.1 (+21%)	8.3 (-8%)	77.1

2025 operating revenue guidance:
Decrease by a mid-single-digit percentage vs 2024

Operating revenue €Mn



Specialty pharma business €Mn



Heparin franchise* €69.6m **+24%**
45% of operating revenue

Enoxaparin sales €40.6m **+17%**

- ✓ ROVI expects a greater concentration of orders from partners in H1 2025 vs H2 2025.
- ✓ ROVI expects full year sales to decrease by a low-single-digit percentage in 2025 vs to 2024.

Bemiparin sales €27.1m **+38%**

- ✓ Sales of bemiparin increased mainly because of higher orders from partners in China, Turkey and Jordan.
- ✓ ROVI expects full year sales to increase by a low-single-digit percentage in 2025 vs 2024.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

Other prescription-based pharmaceutical products

Neparvis® €13.6m **+11%**

Okedi® €12.6m **+133%**

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Marketed in Europe, Australia & Taiwan.


CDMO⁽¹⁾ business €Mn




⁽¹⁾Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first quarter of 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

Gross profit €Mn



SG&A expenses €Mn



R&D expenses €Mn €6.2


+2%

Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Approved	Marketed in Europe, and in Australia & Taiwan
Letrozole ISM®, annual	Breast Cancer	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole SIE ⁽¹⁾ , quarterly	Breast Cancer	Completion of phase I	Phase I: positive readout confirms superior estrogen suppression vs Femara® and allows progression to phase III clinical trial
Risperidone, quarterly	Schizophrenia	Completion of phase I	Phase I: positive readout allows progression to phase III clinical trial
Concentrated on improving posology for already approved compounds, which benefits risk / reward profile Multiple FDA / GMP approved facilities to support the platform			

(1) Superior Inhibition of Estrogen

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first quarter of 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

EBITDA €Mn




EBITDA Pre-R&D⁽¹⁾
€Mn

€36.5m

+14%

Net profit €Mn



Net profit Pre-R&D⁽¹⁾
€Mn

€23.0m

+16%

(1) Calculated excluding R&D expenses in Q1 2025 and Q1 2024

News flow

SPECIALTY PHARMA

- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Moderna's product manufacturing progress
- ✓ Announcement of new contracts

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe, and rest of the world
- ✓ Phase III efficacy clinical trial and pk/ bioavailability study of a new three-monthly formulation of letrozole (Letrozole SIE)
- ✓ Phase III efficacy clinical trial and pk/ bioavailability study of risperidone for a 3-monthly injection